Table 2. Effectiveness outcomes.

Parameter	Proximal (ICA) group	Distal (non-ICA) group	P value
Primary efficacy endpoint, n (%)	53/62 (85.5)	78/93 (83.9)	0.78
Secondary efficacy endpoints
Raymond Class (core lab), n (%)			0.78
1	55/62 (88.7)	80/91 (87.9)
2	4/62 (6.5)	8/91 (8.8)
3	3/62 (4.8)	3/91 (3.3)
Raymond Class 1 and 2 combined, n (%)*	59/62 (95.2)	88/91 (96.7)	0.65
Recanalization, n (%)†	4/62 (6.5)	5/92 (5.4)	0.76
Progressive occlusion of target aneurysm (core lab), n (%)			0.61
Same	37/62 (59.7)	55/91 (60.4)
Better	23/62 (37.1)	30/91 (33.0)
Worse	2/62 (3.2)	6/91 (6.6)
Parent artery stenosis >50% (core lab), n (%)	1/62 (1.6)	1/91 (1.1)	0.78
Incidence of stent migration (core lab), n (%)	0/68 (0.0)	0/112 (0.0)	N/A
Incidence of retreatment (site-reported), n (%)‡	2/70 (2.9)	5/112 (4.5)	0.55

^*Composite outcome: complete aneurysm occlusion (100% occlusion – Raymond Class 1) of the treated target lesion on 12-month angiography, in the absence of retreatment, or parent artery stenosis (>50%) at the target location, and no neurological death.

^†Recanalization is defined as a Raymond score of 3 at 12-month visit or retreatment due to recanalization.

^‡Two of the seven subjects had pre-planned staged procedures.

N/Anot available